SCHEMBL3086037

SCHEMBL3086037

CCN(CC)c1nc(C)cc(-c2nc(-c3ccc(CC(=O)O)cc3)no2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 5/20 0.41
S1PR5 Q9H228 2/20 0.41
HDAC4 P56524 2/20 0.39
HDAC6 Q9UBN7 1/20 0.39
KMT2A Q03164 4/20 0.39
MAPT P10636 4/20 0.39
HSD17B10 Q99714 2/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
KDM4E B2RXH2 2/20 0.38
MEN1 O00255 3/20 0.38
HPGD P15428 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
TP53 P04637 2/20 0.38
POLB P06746 1/20 0.37
S1PR3 Q99500 4/20 0.37
ALDH1A1 P00352 2/20 0.37
NPC1 O15118 1/20 0.37
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3084222 0.85 S1PR1 (0.51) S1PR1S1PR5KMT2AMAPTNPSR1
SCHEMBL3086366 0.83 S1PR1 (0.40) S1PR1S1PR5KMT2AMAPTNPSR1
SCHEMBL3280060 0.82 S1PR1 (0.47) S1PR1S1PR5HDAC4HDAC6KMT2A
SCHEMBL3092682 0.81 S1PR1 (0.47) S1PR1KMT2AMAPTCYP2C19S1PR3
SCHEMBL1179159 0.80 S1PR1 (0.38) S1PR1MAPTHSD17B10KDM4EHPGD
SCHEMBL3088331 0.79 CA1 (0.40) S1PR1KMT2AMAPTNPSR1KDM4E
SCHEMBL3088027 0.77 CA1 (0.39) S1PR1HDAC4HDAC6KMT2AMAPT
SCHEMBL3084808 0.75 S1PR1 (0.46) S1PR1S1PR3
SCHEMBL1179435 0.74 S1PR1 (0.36) S1PR1MAPTHPGDPOLBS1PR3
SCHEMBL3218653 0.73 S1PR1 (0.50) S1PR1S1PR5S1PR3TPH1S1PR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2217594-B1 NOVEL PYRIMIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2014-01-08 EP disclosed
US-8299086-B2 Pyrimidine derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2012-10-30 US disclosed
US-20100234346-A1 NOVEL PYRIMIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-09-16 US disclosed
EP-2217594-A2 NOVEL PYRIMIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-08-18 EP disclosed
WO-2009057079-A2 NOVEL PYRIMIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234346-A1 NOVEL PYRIMIDINE DERIVATIVES TYMP, TYMS, DPYD S1PR1 989/4885S1PR5 854/4885HDAC4 2178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.